Rationale and design of the randomised clinical trial comparing early medication change (EMC) strategy with treatment as usual (TAU) in patients with major depressive disorder--the EMC trial.
BACKGROUND
In major depressive disorder (MDD), the traditional belief of a delayed onset of antidepressants' effects has lead to the concept of current guidelines that treatment durations should be between 3-8 weeks before medication change in case of insufficient outcome. Post hoc analyses of clinical trials, however, have shown that improvement usually occurs within the first 10-14 days of treatment and that such early improvement (Hamilton Depression Rating Scale [HAMD] decrease >or=20%) has a substantial predictive value for final treatment outcome. Even more important, non-improvement (HAMD decrease <20%) after 14 days of treatment was found to be highly predictive for a poor final treatment outcome.


METHODS
The EMC trial is a phase IV, multi-centre, multi-step, randomized, observer-blinded, actively controlled parallel-group clinical trial to investigate for the first time prospectively, whether non-improvers after 14 days of antidepressant treatment with an early medication change (EMC) are more likely to attain remission (HAMD-17 <or=7) on treatment day 56 compared to patients treated according to current guideline recommendation (treatment as usual; TAU). In level 1 of the EMC trial, non-improvers after 14 days of antidepressant treatment will be randomised to an EMC strategy or TAU. The EMC strategy for this study schedules a first medication change on day 15; in case of non-improvement between days 15-28, a second medication change will be performed. TAU schedules the first medication change after 28 days in case of non-response (HAMD-17 decrease <50%). Both interventions will last 42 days. In levels 2 and 3, EMC strategies will be compared with TAU strategies in improvers on day 14, who experience a stagnation of improvement during the course of treatment. The trial is supported by the German Federal Ministry of Education and Research (BMBF) and will be conducted in cooperation with the BMBF funded Interdisciplinary Centre Clinical Trials (IZKS) at the University Medical Centre Mainz and at six clinical trial sites in Germany.


CONCLUSIONS
If the EMC strategies lead to significantly more remitters, changes of clinical practice, guidelines for the treatment of MDD as well as research settings can be expected.


BACKGROUND
Clincaltrials.gov Identifier: NCT00974155; EudraCT: 2008-008280-96.
Tadić
André
A
Department of Psychiatry and Psychotherapy, University Medical Centre Mainz, Germany. tadic@uni-mainz.de
Gorbulev
Stanislav
S
Dahmen
Norbert
N
Hiemke
Christoph
C
Braus
Dieter F
DF
Röschke
Joachim
J
van Calker
Dietrich
D
Wachtlin
Daniel
D
Kronfeld
Kai
K
Gorbauch
Thorsten
T
Seibert-Grafe
Monika
M
Lieb
Klaus
K
D000928:Antidepressive Agents / Q000008:administration & dosage* / Q000009:adverse effects; D003865:Major Depressive Disorder / Q000188:drug therapy* / Q000523:psychology; D004334:Drug Administration Schedule; D005858:Germany; D019983:Guideline Adherence; D006801:Humans; D017410:Practice Guidelines as Topic; D011446:Prospective Studies; D011569:Psychiatric Status Rating Scales; D012107:Research Design; D017211:Treatment Failure; D016896:Treatment Outcome
D000928:Antidepressive Agents